drugset / Trial / NCT06155110

A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

NCT06155110 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This study aim to investigate the myocardium protection effect of cardiomyopeptidin in patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial enhanced MRI.

Timeline

Start
2019-11-01
Primary completion
2025-03-01
Completion
2025-05-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject cardiomyopeptidin Unknown 3 mg/kg Intravenous